The landscape of eczema treatment has seen significant advancements in 2024, with new medications receiving FDA approval and several therapies on the horizon for 2025. Since our last roundup in December 2023, the FDA has granted approval for two new treatments, marking a major step forward in the management of eczema. Additionally, there are several promising therapies expected to undergo review in the coming year.
New Eczema Treatments Approved in 2024
Zoryve (Roflumilast Cream 0.15%): In July 2024, the FDA approved Zoryve, a topical cream developed by Arcutis Biotherapeutics, for the treatment of mild to moderate atopic dermatitis in both adults and children aged six and older. Zoryve works as a PDE4 inhibitor and is a significant addition to eczema treatments. The cream’s approval follows the prior approval of Zoryve foam (0.3%) for treating seborrheic dermatitis in patients aged nine and older. The new cream formulation offers a valuable option for those dealing with atopic dermatitis. For more information, frequently asked questions about Zoryve are available.
Ebglyss (Lebrikizumab-LBKZ): In September 2024, the FDA approved Ebglyss, a biologic from Eli Lilly and Company, for treating moderate-to-severe atopic dermatitis. Ebglyss, an IL-13 inhibitor biologic, is indicated for patients aged 12 years and older who weigh at least 88 pounds (40 kg). This approval represents another important step in providing targeted therapies for individuals with more severe forms of eczema. More details on Ebglyss can be found in its FAQ section.
Looking Ahead: Eczema Treatments for 2025
Delgocitinib Cream (20 mg/g, 2%): A significant development is on the horizon for the treatment of chronic hand eczema (CHE). The FDA has accepted a filing for delgocitinib, a topical pan-JAK inhibitor developed by LEO Pharma. Delgocitinib cream is being reviewed for the treatment of moderate to severe CHE in adults who have not responded adequately to other treatments or where topical corticosteroids are unsuitable. This would be the first prescription treatment specifically targeting chronic hand eczema, providing much-needed relief for affected patients.
Nemolizumab (Nemluvio): Another promising biologic therapy under FDA review is nemolizumab (Nemluvio), an IL-31 inhibitor developed by Galderma. Nemolizumab is designed to treat moderate to severe atopic dermatitis in adolescents and adults. This biologic was approved in August 2024 for the treatment of prurigo nodularis in adults, and its potential use in eczema is eagerly anticipated.
VTAMA (Tapinarof 1%): The FDA is currently reviewing VTAMA, a nonsteroidal topical cream from Dermavant Sciences. VTAMA, an aryl hydrocarbon receptor agonist, is already approved for treating plaque psoriasis in adults. It is now under review for approval to treat atopic dermatitis in both adults and children aged two years and older. If approved, VTAMA would offer an important nonsteroidal option for eczema management.
Conclusion
2024 has brought exciting new treatment options for eczema, from topical creams to biologic therapies. Looking ahead to 2025, several promising treatments are on the verge of approval, offering hope for improved outcomes for patients with chronic and severe eczema. As the FDA continues to evaluate these therapies, patients can expect even more choices in managing this complex condition.
Related topics:
